全文获取类型
收费全文 | 6096篇 |
免费 | 389篇 |
国内免费 | 16篇 |
专业分类
耳鼻咽喉 | 28篇 |
儿科学 | 196篇 |
妇产科学 | 139篇 |
基础医学 | 1056篇 |
口腔科学 | 67篇 |
临床医学 | 685篇 |
内科学 | 1132篇 |
皮肤病学 | 187篇 |
神经病学 | 558篇 |
特种医学 | 129篇 |
外科学 | 498篇 |
综合类 | 79篇 |
一般理论 | 4篇 |
预防医学 | 780篇 |
眼科学 | 170篇 |
药学 | 313篇 |
中国医学 | 17篇 |
肿瘤学 | 463篇 |
出版年
2023年 | 52篇 |
2022年 | 64篇 |
2021年 | 155篇 |
2020年 | 86篇 |
2019年 | 118篇 |
2018年 | 154篇 |
2017年 | 122篇 |
2016年 | 147篇 |
2015年 | 160篇 |
2014年 | 217篇 |
2013年 | 323篇 |
2012年 | 402篇 |
2011年 | 487篇 |
2010年 | 261篇 |
2009年 | 244篇 |
2008年 | 423篇 |
2007年 | 370篇 |
2006年 | 396篇 |
2005年 | 428篇 |
2004年 | 349篇 |
2003年 | 340篇 |
2002年 | 299篇 |
2001年 | 58篇 |
2000年 | 49篇 |
1999年 | 44篇 |
1998年 | 60篇 |
1997年 | 51篇 |
1996年 | 44篇 |
1995年 | 41篇 |
1994年 | 39篇 |
1993年 | 46篇 |
1992年 | 32篇 |
1991年 | 25篇 |
1990年 | 25篇 |
1989年 | 18篇 |
1988年 | 24篇 |
1987年 | 12篇 |
1986年 | 14篇 |
1985年 | 20篇 |
1984年 | 23篇 |
1983年 | 19篇 |
1982年 | 23篇 |
1981年 | 13篇 |
1980年 | 15篇 |
1979年 | 12篇 |
1978年 | 12篇 |
1976年 | 15篇 |
1975年 | 23篇 |
1974年 | 14篇 |
1973年 | 17篇 |
排序方式: 共有6501条查询结果,搜索用时 15 毫秒
51.
Sosa Sylvia Kogan Michael D. Garcia Stephanie Strobino Donna M. Minkovitz Cynthia S. 《Maternal and child health journal》2021,25(2):221-229
Maternal and Child Health Journal - The Health Resources and Services Administration’s Maternal and Child Health Bureau (HRSA MCHB) developed a three-tiered performance measure framework for... 相似文献
52.
Somba Magreat Kaaya Sylvia Siril Hellen Oljemark Kicki Ainebyona Donald McAdam Elspeth Todd James Andrew Irene McAdam Keith Simwinga Alice Mleli Neema Makongwa Samwel Haberlen Sabina Fawzi Mary C. Smith 《Prevention science》2021,22(7):940-949
Prevention Science - The NAMWEZA intervention was implemented, using a ten-session group format, to build skills targeting psychosocial vulnerabilities and enhancing HIV prevention among people... 相似文献
53.
Erin Tutty Chriselle Hickerton Bronwyn Terrill Belinda McClaren Rigan Tytherleigh Elaine Stackpoole Jaqueline Savard Ainsley Newson Anna Middleton Amy Nisselle Marie Cusack Melissa Adamski Clara Gaff Sylvia Metcalfe 《Health expectations》2021,24(2):670
BackgroundConsumer genomic testing for nutrition and wellness, (nutritional genomics), is becoming increasingly popular. Concurrently, health‐care practitioners (HPs) working in private practice (including doctors interested in integrative medicine, private genetic counsellors, pharmacists, dieticians, naturopaths and nutritionists) are involved as test facilitators or interpreters.ObjectiveTo explore Australian consumers’ and HPs’ experiences with nutrigenomic testing.MethodSemi‐structured in‐depth interviews were conducted using predominantly purposive sampling. The two data sets were analysed individually, then combined, using a constant comparative, thematic approach.ResultsOverall, 45 interviews were conducted with consumers (n = 18) and HPs (n = 27). Many of the consumer interviewees experienced chronic ill‐health. Nutrigenomic testing was perceived as empowering and a source of hope for answers. While most made changes to their diet/supplements post‐test, self‐reported health improvements were small. A positive relationship with their HP appeared to minimize disappointment. HPs’ adoption and views of nutrigenomic testing varied. Those enthusiastic about testing saw the possibilities it could offer. However, many felt nutrigenomic testing was not the only ‘tool’ to utilize when offering health care.DiscussionThis research highlights the important role HPs play in consumers’ experiences of nutrigenomics. The varied practice suggests relevant HPs require upskilling in this area to at least support their patients/clients, even if nutrigenomic testing is not part of their practice.Patient or public contributionAdvisory group included patient/public group representatives who informed study design; focus group participants gave feedback on the survey from which consumer interviewees were sourced. This informed the HP data set design. Interviewees from HP data set assisted with snowball sampling. 相似文献
54.
Pauline Vetter Arnaud G. LHuillier Maria F. Montalbano Fiona Pigny Isabella Eckerle Giulia Torriani Sylvia Rothenberger Florian Laubscher Samuel Cordey Laurent Kaiser Manuel Schibler 《Emerging infectious diseases》2021,27(2):658
We report 3 cases of Puumala virus infection in a family in Switzerland in January 2019. Clinical manifestations of the infection ranged from mild influenza-like illness to fatal disease. This cluster illustrates the wide range of clinical manifestations of Old World hantavirus infections and the challenge of diagnosing travel-related hemorrhagic fevers. 相似文献
55.
Lobo Sylvia J. Lin Jessica G. Vais Simone Wang Dongyu Adegoke Tejumola M. Wu Wan-Ju Steer-Massaro Courtney 《Journal of immigrant and minority health / Center for Minority Public Health》2022,24(1):111-117
Journal of Immigrant and Minority Health - Although multiple studies have shown that resettled refugee women are less likely to receive preventative cancer screenings like pap smears and... 相似文献
56.
Stefan Schwarz Nina Rahimi Daria Kifjak Moritz Muckenhuber Martin Watzenböck Alberto Benazzo Peter Jaksch Sylvia Knapp Walter Klepetko Konrad Hoetzenecker the Vienna Lung Transplant Group 《American journal of transplantation》2021,21(6):2132-2144
Objectifying donor lung quality is difficult and currently there is no consensus. Several donor scoring systems have been proposed in recent years. They all lack large-scale external validation and widespread acceptance. A retrospective evaluation of 2201 donor lungs offered to the lung transplant program at the Medical University of Vienna between January 2010 and June 2018 was performed. Five different lung donor scores were calculated for each offer (Oto, ET, MALT, UMN-DLQI, and ODSS). Prediction of organ utilization, 1-year graft survival, and long-term outcome were analyzed for each score. 1049 organs were rejected at the initial offer (group I), 209 lungs declined after procurement (group II), and 841 lungs accepted and transplanted (group III). The Oto score was superior in predicting acceptance of the initial offer (AUC: 0.795; CI: 0.776–0.815) and actual donor utilization (AUC: 0.660; CI: 0.618–0.701). Prediction of 1-year graft survival was best using the MALT score, Oto score, and UMN-DLQI. Stratification of early outcome by MALT was significant for length of mechanical ventilation (LMV), PGD3 rates, ICU stay and hospital stay, and in-hospital-mortality, respectively. To the best of our knowledge, this study is the largest validation analysis comparing currently available donor scores. The Oto score was superior in predicting organ utilization, and MALT score and UMN-DLQI for predicting outcome after lung transplantation. 相似文献
57.
Beverly A. Teicher Enrique Alvarez Sotomayor Zhen Dong Huang Gulshan Ara Sylvia Holden Vrinda Khandekar Ying-Nan Chen 《Cancer chemotherapy and pharmacology》1993,33(3):229-238
Tetrahydrocortisol, -cyclodextrin tetradecasulfate, and minocycline used alone or in combination are not very cytotoxic toward EMT-6 mouse mammary tumor cells growing in monolayer. Tetrahydrocortisol (100 M, 24 h) and -cyclodextrin tetradecasulfate (100 M, 24 h) protected EMT-6 cells from the cytotoxicity of CDDP, melphalan, 4-hydroperoxycyclophosphamide, BCNU, and X-rays under various conditions of oxygenation and pH. Minocycline (100 M, 24 h) either had no effect upon or was additive with the antitumor alkylating agents or X-rays in cytotoxic activity toward the EMT-6 cells in culture. The combination of the three modulators either had no effect upon or was to a small degree protective against the cytotoxicity of the antitumor alkylating agents or X-rays. The Lewis lung carcinoma was chosen for primary tumor growth-delay studies and tumor lung-metastases studies. Tetrahydrocortisol and -cyclodextrin tetradecasulfate were given in a 1:1 molar ratio by continuous infusion over 14 days, and minocycline was given i.p. over 14 days, from day 4 to day 18 post tumor implantation. The combination of tetrahydrocortisol/-cyclodextrin tetradecasulfate diminished the tumor growth delay induced by CDDP and melphalan and produced modest increases in the tumor growth delay produced by cyclophosphamide and radiation. Minocycline co-treatment increased the tumor growth delay produced by CDDP, melphalan, radiation, bleomycin, and, especially cyclophosphamide, where 4 of 12 animals receiving minocycline (14×5mg/kg, days 4–18) and cyclophosphamide (3×150 mg/kg, days, 7, 9, 11) were long-term survivors. The 3 modulators given in combination produced further increases in tumor growth delay with all of the cytotoxic therapies, and 5 of 12 of the animals treated with the 3-modulator combination and cyclophosphamide were long-term survivors. Although neither tetrahydrocortisol/-cyclodextrin tetradecasulfate, minocycline, nor the three modulator combination impacted the number of lung metastases, there was a decrease in the number of large lung metastases. Treatment with the cytotoxic therapies alone reduced the number of lung metastases. Addition of the modulators to treatment with the cytotoxic therapies resulted in a further reduction in the number of lung metastases. These results indicate that agents that inhibit the breakdown of the extracellular matrix can be useful additions to the treatment of solid tumors.Abbreviations 14(SO4)ßCD
-cyclodextrin tetradecasulfate
- THC
tetrahydrocortisol
- CDDP
cis-diamminedichloroplatinum(II)
- 4-HC
4-hydroperoxycyclophosphamide
- BCNU
N,N-bis(2-chloroethyl)-N-nitrosourea
- CAM
chick embryo chorioallantoic membrane; IC50, concentration of a drug required to kill 50% of the cells
This work was supported by NIH grant P01-CA38493 and a grant from Bristol-Myers-Squibb, Inc., Wallingford, Connecticut 相似文献
58.
Clémence Jacquin Emilie Landais Céline Poirsier Alexandra Afenjar Ahmad Akhavi Nathalie Bednarek Caroline Bénech Adeline Bonnard Damien Bosquet Lydie Burglen Patrick Callier Sandra Chantot-Bastaraud Christine Coubes Charles Coutton Bruno Delobel Margaux Descharmes Jean-Michel Dupont Vincent Gatinois Nicolas Gruchy Sarah Guterman Abdelkader Heddar Lucas Herissant Delphine Heron Bertrand Isidor Pauline Jaeger Guillaume Jouret Boris Keren Paul Kuentz Cedric Le Caignec Jonathan Levy Nathalie Lopez Zoe Manssens Dominique Martin-Coignard Isabelle Marey Cyril Mignot Chantal Missirian Céline Pebrel-Richard Lucile Pinson Jacques Puechberty Sylvia Redon Damien Sanlaville Marta Spodenkiewicz Anne-Claude Tabet Alain Verloes Gaelle Vieville Catherine Yardin François Vialard Martine Doco-Fenzy 《American journal of medical genetics. Part A》2023,191(2):445-458
Chromosome 1p36 deletion syndrome (1p36DS) is one of the most common terminal deletion syndromes (incidence between 1/5000 and 1/10,000 live births in the American population), due to a heterozygous deletion of part of the short arm of chromosome 1. The 1p36DS is characterized by typical craniofacial features, developmental delay/intellectual disability, hypotonia, epilepsy, cardiomyopathy/congenital heart defect, brain abnormalities, hearing loss, eyes/vision problem, and short stature. The aim of our study was to (1) evaluate the incidence of the 1p36DS in the French population compared to 22q11.2 deletion syndrome and trisomy 21; (2) review the postnatal phenotype related to microarray data, compared to previously publish prenatal data. Thanks to a collaboration with the ACLF (Association des Cytogénéticiens de Langue Française), we have collected data of 86 patients constituting, to the best of our knowledge, the second-largest cohort of 1p36DS patients in the literature. We estimated an average of at least 10 cases per year in France. 1p36DS seems to be much less frequent than 22q11.2 deletion syndrome and trisomy 21. Patients presented mainly dysmorphism, microcephaly, developmental delay/intellectual disability, hypotonia, epilepsy, brain malformations, behavioral disorders, cardiomyopathy, or cardiovascular malformations and, pre and/or postnatal growth retardation. Cardiac abnormalities, brain malformations, and epilepsy were more frequent in distal deletions, whereas microcephaly was more common in proximal deletions. Mapping and genotype–phenotype correlation allowed us to identify four critical regions responsible for intellectual disability. This study highlights some phenotypic variability, according to the deletion position, and helps to refine the phenotype of 1p36DS, allowing improved management and follow-up of patients. 相似文献
59.
Papillary carcinomas (PCs) of thyroid are among the most common but least aggressive human malignancies. The factors explaining
the indolence of these tumors are unknown but host-tumor immune interactions may play a role. This study was designed to determine
if there is morphologic evidence of these. Frozen tissues collected from 21 PCs, 4 follicular adenomas (FAs), 4 follicular
carcinomas (FCs), and 11 nodular hyperplasias (NHs) were stained immunohistochemically for HLA-D antigens, lymphocyte and
macrophage markers; results were graded numerically. Paraffin-embedded tumors (35 PCs, 10 FAs, and 10 FCs) were stained for
S-100 protein to detect Langerhans' cells (LCs). Diffuse staining for HLA-D antigens and heavy mononuclear infiltrates were
found more commonly in PCs compared to follicular neoplasms (FNs) or NHs. No consistent relationship was found between lymphocyte/macrophage
infiltrates and expression of HLA-D antigens. The largest number of LCs was in PCs (median 11.8 cells/standard microscopic
field [c/smf]), fewer cells were found in FA (3.7 c/smf), and the least in FC (0.05 c/smf). Features of host-tumor interaction
including HLA-D expression and infiltrates with lymphocyte macrophages and LC are more strongly expressed in PC than other
tumors. This may play a role in explaining their biological behavior. 相似文献
60.
Thomas Wieland Klaus Liedel Sylvia Kaldenberg-Stasch Dagmar Meyer zu Heringdorf Martina Schmidt Karl H. Jakobs 《Naunyn-Schmiedeberg's archives of pharmacology》1995,351(4):329-336
Receptor-induced binding of the stable GTP analogue, guanosine 5-[-thio]triphosphate (GTP [S]), to guanine nucleotide-binding regulatory proteins (G proteins) was measured in various permeabilized cells. In myeloid differentiated human leukemia (HL-60) cells, permeabilized with either digitonin, streptolysin O or Staphylococcus aureus -toxin, binding of GTP [S] induced by three distinct chemoattractant receptors was observed. The extent of receptor-stimulated GTP [S] binding (maximally about 2-fold) was independent of the type of permeabilizing agent used. In human erythroleukemia cells permeabilized with digitonin, agonist activation of thrombin and neuropeptide Y receptors increased GTP [S] binding by 1.8- and 1.5-fold, respectively. Finally, in adherently grown human embryonic kidney cells permeabilized with digitonin, activation of the stably expressed human muscarinic m3 receptor increased GTP[S] binding by about 1.6-fold. In digitonin-permeabilized HL-60 cells, a quantitative analysis of formyl peptide receptors and interacting G proteins was performed. About 50,000 formyl peptide receptors per cell were detected. Agonist binding to these receptors was fully sensitive to regulation by guanine nucleotides and pertussis toxin. The number of high-affinity GTP [S] binding sites, most likely representing heterotrimeric G proteins, was calculated to be about 670,000 per cell. Stimulation of formyl peptide receptors led to the activation of about 130,000 of high-affinity GTP [S] binding sites, indicating a ratio of about three activated G proteins per one agonist-activated receptor.Overall, this study indicates that receptor-stimulated GTP [S] binding to G proteins in permeabilized cells is a sensitive and rapid method for analyzing receptor-G protein interactions, which can be applied to a variety of cultured cells and for various receptor systems. 相似文献